文献速递淋巴瘤

原发性纵隔B细胞淋巴瘤省略放疗:IELSG37试验结果

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
PubMed 文献 · J Clin Oncol · 2024-08-19

IELSG37随机非劣效性试验评估原发性纵隔B细胞淋巴瘤患者诱导免疫化疗后达完全代谢缓解(CMR)时能否省略巩固放疗。545例入组患者中268例达CMR并随机分配至观察组(132例)或放疗组(136例,30 Gy),30个月无进展生存率观察组96.2%对放疗组98.5%,分层风险比1.47(95%CI 0.34-6.28),绝对风险差0.68%(95%CI -0.97-7.46),5年总生存率两组均为99%。

要点

  • 诱导免疫化疗后达CMR的PMBCL患者省略放疗未显示生存受损
  • 30个月PFS观察组96.2%对放疗组98.5%,分层HR 1.47(95%CI 0.34-6.28)
  • Deauville评分5分患者5年PFS和OS显著较差(60.3%和74.6%)

核心结论

  • 这项关于PMBCL放疗的最大随机试验显示,达CMR的患者省略放疗后结局良好,无生存受损。

研究设计与样本

  • IELSG37为随机非劣效性研究,计划样本量540例、预期随机分配376例,实际入组545例。
  • 545例入组患者中268例诱导后达CMR,随机分配至观察组(n=132)或巩固放疗组(n=136,30 Gy)。
  • 主要终点为随机分配后30个月无进展生存率,非劣效界值10%(假设两组30个月PFS均为85%)。
  • 因观察到的事件数远低于预期,主要终点分析在≥95%患者随访≥30个月时进行。
  • 未随机分配的患者按当地政策管理。

主要发现

  • 30个月PFS观察组为96.2%,放疗组为98.5%,分层风险比1.47(95%CI 0.34-6.28),绝对风险差0.68%(95%CI -0.97-7.46)。
  • 两组5年总生存率均为99%。
  • Deauville评分4分患者中86%仅接受放疗,5分患者中57%仅接受放疗。
  • Deauville评分4分患者5年PFS和OS分别为95.8%和97.5%,与随机分配患者无显著差异。
  • Deauville评分5分患者5年PFS和OS显著较差,分别为60.3%和74.6%。

临床怎么用

  • 诱导免疫化疗后达CMR的PMBCL患者可考虑省略巩固放疗。
  • 未随机分配患者的治疗按当地政策管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. METHODS: The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted in patients with PMBCL with complete metabolic response (CMR) after induction immunochemotherapy. The primary end point was progression-free survival (PFS) at 30 months after random assignment. Patients with CMR were randomly assigned to observation or consolidation radiotherapy (30 Gy). With a noninferiority margin of 10% (assuming a 30-month PFS of 85% in both arms), a sample size of 540 patients was planned with 376 expected to be randomly assigned. RESULTS: The observed events were considerably lower than expected; therefore, primary end point analysis was conducted when ≥95% of patients were followed for ≥30 months. Of the 545 patients enrolled, 268 were in CMR after induction and were randomly assigned to observation (n = 132) or radiotherapy (n = 136). The 30-month PFS was 96.2% in the observation arm and 98.5% in the radiotherapy arm, with a stratified hazard ratio of 1.47 (95% CI, 0.34 to 6.28) and absolute risk difference of 0.68% (95% CI, -0.97 to 7.46). The 5-year overall survival (OS) was 99% in both arms. Nonrandomized patients were managed according to local policies. Radiotherapy was the only treatment in 86% of those with Deauville score (DS) 4 and in 57% of those with DS 5. The 5-year PFS and OS of patients with DS 4 (95.8% and 97.5%, respectively) were not significantly different from those of randomly assigned patients. Patients with DS5 had significantly poorer 5-year PFS and OS (60.3% and 74.6%, respectively). CONCLUSION: This study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Martelli M, Ceriani L, Ciccone G, et al. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. J Clin Oncol. 2024. PMID: 39159403. doi:10.1200/JCO-24-01373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。